# Tempus AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tempus-ai

- Industry: Healthcare IT
- Headquarters: Chicago, US
- Website: www.tempus.com
- Total disclosed funding: $1.3B
- Latest round: Series G (Apr 1, 2024)
- Investors on record: 9

## About

Tempus AI, Inc. is a US-based company specializing in AI-driven precision medicine solutions that enhance patient care through advanced data analysis and technology integration.Founded in 2015 and headquartered in Chicago, US, Tempus AI, Inc. focuses on precision medicine by combining data analytics with clinical insights. The company has completed 15 deals, with its most recent funding round being Series G, raising USD 200.00 mn, bringing the total amount raised to USD 200.00 mn. The firm is co-founded by Anthony Ingram and Ed Dacanay, with Francesco Congiu serving as CEO. Tempus has established a strong presence in the healthcare sector, utilizing innovative strategies to adapt to market needs.Tempus offers a comprehensive suite of AI-enabled precision medicine solutions that improve patient care through sophisticated data analysis. Their primary offerings include genomic profiling, algorithmic tests, and advanced software that aids healthcare providers in making informed treatment decisions. Notable products like Tempus Hub and Tempus One support oncologists and healthcare systems by facilitating data integration and personalized treatment matching. Additionally, Tempus enhances clinical trial matching with digital pathology solutions, helping pharmaceutical partners leverage real-world data in drug development.For the year 2024, Tempus reported revenue of USD 693.40 mn, accompanied by an EBITDA of USD -647.10 mn. The company's revenue model is built on subscriptions and partnerships with healthcare providers, enabling them to utilize their extensive range of services under tailored contracts.In June 2024, Tempus AI, Inc. raised USD 410.70 mn in an IPO on the New York Stock Exchange, selling 11.1 million shares at USD 37 each, valuing the company at approximately USD 6.1 bn. The company aims to utilize the recent funding to launch new products, expand into European and Asian markets, and enhance their healthcare technology offerings. Tempus has also granted underwriters a 30-day option to purchase an additional 1.67 million shares, indicating continued commitment to growth and market expansion.

## Funding rounds

- Series G, Apr 1, 2024, $200M — SB Investment Advisers
- Series G, Dec 10, 2020, $400M — T Rowe Price, Google Inc., Novo Holdings, Franklin Templeton, Baillie Gifford
- Series G, Mar 13, 2020, $200M — New Enterprise Associates, T Rowe Price, Novo Holdings, Franklin Templeton, Baillie Gifford
- Series F, May 30, 2019, $200M — New Enterprise Associates, T Rowe Price, Baillie Gifford, Revolution Ventures, Novo Holdings, Franklin Templeton
- Series E, Aug 29, 2018, $111M — New Enterprise Associates, T Rowe Price, Baillie Gifford, Revolution Ventures
- Series D, Mar 20, 2018, $80M — New Enterprise Associates, T Rowe Price, Revolution Ventures, Kinship Partners
- Series C, Sep 22, 2017, $70M — New Enterprise Associates, Revolution Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C, Series D, Series E, Series F, Series G
- Revolution Ventures (https://capitalatlas.ai/funds/revolution-ventures) — Series C, Series D, Series E, Series F
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series D, Series E, Series F, Series G
- Kinship Partners — Series D
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series E, Series F, Series G
- Novo Holdings — Series F, Series G
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series F, Series G
- Google Inc. — Series G
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series G